Inside Sionna’s Bid To Normalize CFTR Function

Lab to Lives · Dec 17, 2025 · 29m · transcript

Send us Fan Mail

Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star.

Visit: sionnatx.com

Support the show

________

Reach out to Ivanna Rosendal

Join the conversation on our LinkedIn page

Visit www.labtolives.com

Hosts

Alexander Booth

Chiara Chianese

Ivanna Rosendal Oshida